Bitterroot Bio

Executive Summary

Bitterroot Bio is a private biotechnology company pioneering cardio-immunology, a field targeting the immune system's role in cardiovascular diseases like atherosclerosis. Founded in 2021 and based in San Francisco, the company leverages insights from oncology immunotherapies to develop treatments that address the underlying inflammatory causes of heart disease, rather than just symptoms. Its lead candidate is currently in Phase 2 clinical trials, positioning the company at the forefront of a potentially transformative approach to cardiovascular medicine. The company's platform aims to modulate immune checkpoints to reduce arterial inflammation, which could broadly impact millions of patients with high unmet need. With a strong scientific foundation and early clinical validation, Bitterroot Bio represents a compelling opportunity in the emerging space of immuno-cardiology.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for lead asset50% success
• 2026Series B or C financing round70% success
• 2027Partnership with major cardiovascular or immuno-oncology company40% success